Inhibrx Biosciences, Inc. INBX
99.61
(0.79)
(0.79%)
as of 25 Sep
- Market cap
- $1.5B
- P/E
- 0.0×
Follow INBX
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (1,773.60%) | (354.69%) | (197.85%) | (144.07%) |
+8 more TTM periods Free account |
|
| (75.44%) | (61.03%) | (85.60%) | (77.54%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(118.27%) | (87.95%) | (136.29%) | (119.53%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(8.42) | (8.46) | (8.38) | (9.27) | |
Free Cash Flow |
(131.89) | (131.92) | (129.82) | (143.44) | |
Capital Expenditures |
— | — | (0.03) | (0.04) | |
| Other line items | |||||
Cash ROIC |
(51.39%) | (41.80%) | (55.76%) | (49.47%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.95 | 1.01 | 0.93 | 0.92 | |
Depreciation/Fixed assets |
0.82 | 0.73 | 0.67 | 0.61 | |
Capex/Depreciation |
0.00 | 0.00 | (0.01) | (0.02) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(8.42) | (8.46) | (8.38) | (9.26) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates